Enterome
Biotechnology ResearchÎle-de-France, France11-50 Employees
Enterome is a clinical-stage biotechnology company based in Paris, France, focused on developing immunomodulatory therapies for cancer and immune-related diseases. Its research hinges on a microbiome-inspired drug discovery approach that analyzes gut bacterial proteins to uncover interactions with the human immune system, informing a pipeline of OncoMimics peptide-based immunotherapies aimed at stimulating memory T-cell responses against tumors. The lead candidates include EO2463, which is in Phase 2 for indolent non-Hodgkin lymphoma, and EO2401, which has completed a Phase 2 trial in recurrent glioblastoma, with the company seeking a pharmaceutical partner to advance a pivotal study. Enterome operates in the biotechnology research sector, emphasizing first-in-class strategies and in vivo immune therapies designed to address solid and potentially inflammatory diseases. Recent leadership and collaboration activity, including board appointments and continued participation in industry events, reflects ongoing efforts to advance its clinical program and strategic partnerships.
1-888-653-2347 
support@leadiq.com 
